CAS No. |
1469876-18-3 |
|---|---|
中文名称 |
S-(1-((4-(((1-((S)-37-氨基-34-((4-((((((S)-4,11-二乙基-9-羟基-3,14-二氧代-3,4,12,14-四氢-1H-吡喃并[3',4':6,7]吲哚里西啶并[1,2-b]喹啉-4-基)氧基)羰基)氧基)甲基)苯基)氨基甲酰基)-28,32-二氧代-3,6,9,12,15,18,21,24,30-九氧杂-27,33-二氮杂庚三十七烷基)-1H-1,2,3-三唑-4-基)甲基)氨基甲酰基)环己基)甲基)-2,5-二氧代吡咯烷-3-基)-L-半胱氨酸 |
英文名称 |
S-(1-((4-(((1-((S)-37-amino-34-((4-((((((S)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)carbonyl)oxy)methyl)phenyl)carbamoyl)-28,32-dioxo-3,6,9,12,15,18,21,24,30-nonaoxa-27,33-diazaheptatriacontyl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)cyclohexyl)methyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine |
别名 |
Labetuzumab Govitecan;hMN14-SN38;IMMU 130;IMMU130;IMMU-130;Labetuzumab-SN38;Labetuzumab govitecan (anti-CEACAM5);Labetuzumab govitecan (ADC) |
标准英文名 |
S-(1-((4-(((1-((S)-37-amino-34-((4-((((((S)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)carbonyl)oxy)methyl)phenyl)carbamoyl)-28,32-dioxo-3,6,9,12,15,18,21,24,30-nonaoxa-27,33-diazaheptatriacontyl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)cyclohexyl)methyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine |
分子式 |
C75H102N12O24S |
分子量 |
1587.77 |
精确分子量 |
1586.69 |
SMILES |
CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)OC(=O)OCC4=CC=C(NC(=O)[C@H](CCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN5C=C(CNC(=O)C6CCC(CN7C(=O)CC(SC[C@H](N)C(=O)O)C7=O)CC6)N=N5)C=C4)C3=O)C2=NC2=C1C=C(O)C=C2 |
标准SMILES |
CC[C@@]1(OC(=O)OCC2C=CC(=CC=2)NC(=O)[C@H](CCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN2C=C(CNC(=O)C3CCC(CN4C(=O)C(CC4=O)SC[C@H](N)C(O)=O)CC3)N=N2)C(=O)OCC2C(=O)N3CC4C(=NC5C=CC(O)=CC=5C=4CC)C3=CC1=2 |
用途 |
Labetuzumab govitecan is used in cancer research, such as for colorectal cancer. |
InChIKey |
CBNAAKBWBABMBY-LQCKLLCCSA-N |
|
|
评论 |
|---|